These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 19558194

  • 1. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G, Mehta S.
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [Abstract] [Full Text] [Related]

  • 2. Oral Therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Lefebvre MC, Hunsche E.
    Appl Health Econ Health Policy; 2010; 8(1):69-71; author reply 71-3. PubMed ID: 20238466
    [No Abstract] [Full Text] [Related]

  • 3. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D.
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [Abstract] [Full Text] [Related]

  • 4. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P, Coghlan G.
    Drugs; 2008 Oct; 68(12):1635-45. PubMed ID: 18681488
    [Abstract] [Full Text] [Related]

  • 5. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B, Langleben D, Hirsch AM, Schlesinger RD, Eisenberg MJ, Joyal D, Blenkhorn F, Lesenko L.
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.
    Angalakuditi M, Edgell E, Beardsworth A, Buysman E, Bancroft T.
    J Med Econ; 2010 Jun; 13(3):393-402. PubMed ID: 20608882
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Efficiency of initiation with ambrisentan versus bosentan in the treatment of pulmonary arterial hypertension].
    Villa G, Morano R, Román A, Gil J.
    Farm Hosp; 2013 Jun; 37(5):358-65. PubMed ID: 24128097
    [Abstract] [Full Text] [Related]

  • 16. [Pharmacological treatment of pulmonary hypertension at a turning point].
    Watanabe H.
    Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):165-72. PubMed ID: 24717603
    [No Abstract] [Full Text] [Related]

  • 17. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Steele P, Strange G, Wlodarczyk J, Dalton B, Stewart S, Gabbay E, Keogh A.
    BMC Cardiovasc Disord; 2010 Feb 22; 10():9. PubMed ID: 20170553
    [Abstract] [Full Text] [Related]

  • 18. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, Mühler EG, Ewert P, Lange PE, Berger F, Schulze-Neick I.
    Eur J Clin Invest; 2006 Sep 22; 36 Suppl 3():32-8. PubMed ID: 16919008
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.